About this trial
This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL/s) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.
Eligibility criteria
Qualifiers
Male patients diagnosed with BPH
Clinical diagnosis of BPH with lower urinary tract symptoms.
IPSS ≥ 20 (severe symptoms)
Maximum urinary flow rate (Qmax) ≤ 10 mL/s
Disqualifiers
Prostate cancer (current or history).
Previous prostate surgery
Previous urethral surgery.
Neurogenic bladder dysfunction.
Trial design
Treatments tested in this trial
- Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP)
- Holmium Laser Enucleation of the Prostate (HoLEP)
- Bipolar Transurethral Enucleation of the Prostate (B-TUEP)